Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[Ga-68]MTP220 PET for Pancreatic and Head and Neck Cancer
NCT07026981Phase 1Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ga-68-mtp220 in pancreatic cancer (PC) and head and neck cancer (HNC). Primary endpoints: Biodistribution of [Ga-68]MTP220 at 2.5 hours and Radiation dosimetry of [Ga-68]MTP220 at 2.5 hours. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ga-68-mtp220
03
Conditions
pancreatic cancer (PC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07026981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026981.